The correlation between diabetic retinopathy and serum biochemical indexes

doi:10.3877/cma.j.issn.2095-2007.2019.03.008

Abstract

Abstract:

Diabetic retinopathy (DR) is a microangiopathy lesion which occurs in diabetic patients′ eyes. It can cause vision loss and seriously reduce patient′s life quality. The pathogenesis of DR is still uncertain. The main viewpoint is that long-term chronic hyperglycemia is the basis of the disease, and multiple factors may play a role in phases, contributing to the overall outcome of DR process. Inflammatory factors in intraocular fluid have been confirmed to be associated with DR, thus intraocular drug therapy is given in clinic. In view of shortcomings of intraocular injection drug and the influence of serum inflammatory factors on the development of DR, this paper summarizes the relationship between serum biochemical indices and DR.

Key words: Diabetic retinopathy, Serum, Cytokine, Oxidative stress

Shan Jiang, Dan Zhu, Yong Tao. The correlation between diabetic retinopathy and serum biochemical indexes[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2019, 09(03): 172-176.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2019.03.008

https://zhykyxzz.cma-cmc.com.cn/EN/Y2019/V09/I03/172

Figures/Tables 3

References 57

[1]	Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030[J]. Diabetes Res Clin Pract, 2011, 94(3): 311-321.
[2]	Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J]. Eye Vis (Lond), 2015, 2: 17.
[3]	Ola MS, Nawaz MI, Siddiquei MM, et al. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy[J]. J Diabetes Complications, 2012, 26(1): 56-64.
[4]	Semenza GL. HIF-1: using two hands to flip the angiogenic switch[J]. Cancer Metastasis Rev, 2000, 19(1-2): 59-65.
[5]	Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, et al. Diabetic macular edema pathophysiology: vasogenic versus inflammatory[J]. J Diabetes Res, 2016, 2016: 2156273.
[6]	Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family[J]. Oncogene, 1990, 5(4): 519-524.
[7]	Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF[J]. Open Ophthalmology Journal, 2013, 7(1): 4-10.
[8]	Geraldes P, Hiraoka-Yamamoto J, Matsumoto M, et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy[J]. Nat Med, 2009, 15(11): 1298-1306.
[9]	Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease[J]. Prog Retin Eye Res, 2003, 22(1): 1-29.
[10]	Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(7): 915-930.
[11]	Kern TS. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy[J]. Exp Diabetes Res, 2007, 2007: 95103.
[12]	Adamis AP. Is diabetic retinopathy an inflammatory disease？[J]. Br J Ophthalmol, 2002, 86(4): 363-365.
[13]	Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokines IL-1beta, IL-6, TNF-alpha and VEGF have influence on the development of diabetic retinopathy[J]. Folia Med (Plovdiv), 2011, 53(2): 44-50.
[14]	Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy[J]. Int J Mol Sci, 2018, 19(4): E942.
[15]	Ben-Mahmud BM, Chan WH, Abdulahad RM, et al. Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy[J]. Diabetologia, 2006, 49(9): 2185-2191.
[16]	Fante RJ, Gardner TW, Sundstrom JM. Current and future management of diabetic retinopathy: a personalized evidence-based approach[J]. Diabetes Manag (Lond), 2013, 3(6): 481-494.
[17]	Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy[J]. Diabetes, 2005, 54(5): 1559-1565.
[18]	Roy MS, Roy A, Brown S. Increased urinary-free cortisol outputs in diabetic patients[J]. J Diabetes Complications, 1998, 12(1): 24-27.
[19]	Hang H, Yuan S, Yang Q, et al. Multiplex bead array assay of plasma cytokines in type 2 diabetes mellitus with diabetic retinopathy[J]. Mol Vis, 2014, 20: 1137-1145.
[20]	Loukovaara S, Piippo N, Kinnunen K, et al. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2017, 95(8): 803-808.
[21]	Chen H, Zhang X, Liao N, et al. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy[J]. BMC Ophthalmol, 2017, 17(1): 176.
[22]	Koya D, King GL. Protein kinase C activation and the development of diabetic complications[J]. Diabetes, 1998, 47(6): 859-866.
[23]	Semeraro F, Cancarini A, dell′ Omo R, et al. Diabetic retinopathy: vascular and inflammatory disease[J]. J Diabetes Res, 2015, 2015: 582060.
[24]	Jonas JB, Jonas RA, Neumaier M, et al. Cytokine concentration in aqueous humor of eyes with diabetic macular edema[J]. Retina, 2012, 32(10): 2150-2157.
[25]	Simó R, Hernández C, European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications[J]. Br J Ophthalmol, 2012, 96(10): 1285-1290.
[26]	Santiago AR, Gaspar JM, Baptista FI, et al. Diabetes changes the levels of ionotropic glutamate receptors in the rat retina[J]. Mol Vis, 2009, 15: 1620-1630.
[27]	Dal Monte M, Petrucci C, Cozzi A, et al. Somatostatin inhibits potassium-evoked glutamate release by activation of the sst(2) somatostatin receptor in the mouse retina[J]. Naunyn Schmiedebergs Arch Pharmacol, 2003, 367(2): 188-192.
[28]	Kouvidi E, Papadopoulou-Daifoti Z, Thermos K. Somatostatin modulates dopamine release in rat retina[J]. Neurosci Lett, 2006, 391(3): 82-86.
[29]	Cervia D, Catalani E, Dal Monte M, et al. Vascular endothelial growth factor in the ischemic retina and its regulation by somatostatin[J]. J Neurochem, 2012, 120(5): 818-829.
[30]	Ray C, Carney S, Morgan T, et al. Somatostatin as a modulator of distal nephron water permeability[J]. Clin Sci (Lond), 1993, 84(4): 455-460.
[31]	Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age-related macular degeneration[J]. Invest Ophthalmol Vis Sci, 2000, 41(8): 2329-2335.
[32]	Hernández C, Carrasco E, Casamitjana R, et al. Somatostatin molecular variants in the vitreous fluid: a comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects[J]. Diabetes Care, 2005, 28(8): 1941-1947.
[33]	Boehm BO, Lang GK, Jehle PM, et al. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy[J]. Horm Metabo Res, 2001, 33(5): 300-306.
[34]	Lim LS, Liew G, Cheung N, et al. Mixed messages on systemic therapies for diabetic retinopathy[J]. Lancet, 2010, 376(9751): 1461, 1462.
[35]	Hernández C, García-Ramírez M, Corraliza L, et al. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes[J]. Diabetes, 2013, 62(7): 2569-2578.
[36]	Domingueti CP, Dusse LM, Carvalho Md, et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications[J]. J Diabetes Complications, 2016, 30(4): 738-745.
[37]	Aghadavod E, Khodadadi S, Baradaran A, et al. Role of oxidative stress and inflammatory factors in diabetic kidney disease[J]. Iran J Kidney Dis, 2016, 10(6): 337-343.
[38]	Gupta MM, Chari S. Lipid peroxidation and antioxidant status in patients with diabetic retinopathy[J]. Indian J Physiol Pharmacol, 2005, 49(2): 187-192.
[39]	Dave A, Kalra P, Gowda BH, et al. Association of bilirubin and malondialdehyde levels with retinopathy in type 2 diabetes mellitus[J]. Indian J Endocrinol Metab, 2015, 19(3): 373-377.
[40]	Li C, Miao X, Li F, et al. Oxidative stress-related mechanisms and antioxidant therapy in diabetic retinopathy[J]. Oxid Med Cell Longev, 2017, 2017: 9702820.
[41]	Fariss MW, Chan CB, Patel M, et al. Role of mitochondria in toxic oxidative stress[J]. Mol Interv, 2005, 5(2): 94-111.
[42]	Yoshikawa Y, Murayama A, Adachi Y, et al. Challenge of studies on the development of new Zn complexes (Zn(opt)2) to treat diabetes mellitus[J]. Metallomics, 2011, 3(7): 686-692.
[43]	Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease[J]. Toxicology, 2011, 283(2-3): 65-87.
[44]	Roussel AM, Kerkeni A, Zouari N, et al. Antioxidant effects of zinc supplementation in Tunisians with type 2 diabetes mellitus[J]. J Am Coll Nutr, 2003, 22(4): 316-321.
[45]	Prasad AS. Clinical, immunological, anti-inflammatory and antioxidant roles of zinc[J]. Exp Gerontol, 2008, 43(5): 370-377.
[46]	Zheng Y, Li XK, Wang Y, et al. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators[J]. Hemoglobin, 2008, 32(1-2): 135-145.
[47]	朱鑫淼. 糖尿病视网膜病变患者血清和尿液中微量元素的变化[D]. 沈阳：中国医科大学，2014.
[48]	Evans JL, Goldfine ID, Maddux BA, et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction？[J]. Diabetes, 2003, 52(1): 1-8.
[49]	Wilson C. Metabolism: iron metabolism, adiponectin and T2DM——the link with adipocyte insulin resistance[J]. Nat Rev Endocrinol, 2012, 8(12): 696.
[50]	Sales CH, Pedrosa Lde F. Magnesium and diabetes mellitus: their relation[J]. Clin Nutr, 2006, 25(4): 554-562.
[51]	Geiger H, Wanner C. Magnesium in disease[J]. Clin Kidney J, 2012, 5(S1): i25-i38.
[52]	Kim DJ, Xun P, Liu K, et al. Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes[J]. Diabetes Care, 2010, 33(12): 2604-2610.
[53]	Kundu D, Osta M, Mandal T, et al. Serum magnesium levels in patients with diabetic retinopathy[J]. J Nat Sci Biol Med, 2013, 4(1): 113-116.
[54]	Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway[J]. Circulation, 2000, 102(11): 1296-1301.
[55]	Yilmaz MI, Sonmez A, Acikel C, et al. Adiponectin may play a part in the pathogenesis of diabetic retinopathy[J]. Eur J Endocrinol, 2004, 151(1): 135-140.
[56]	赖静怡，张颖栩，黄焕葵. 血清胱抑素C及血脂水平与糖尿病视网膜病变的关系研究[J]. 国际眼科杂志，2015(11)：2003-2005.
[57]	Yang H, Wang C, Guo M, et al. Correlations between peroxisome proliferator activator receptor γ，Cystatin C, or advanced oxidation protein product, and atherosclerosis in diabetes patients[J]. Pathol Res Pract, 2015, 211(3): 235-239.

Please choose a citation manager

Content to export